AbbVie presents 20 IBD abstracts with long-term Skyrizi and Rinvoq data at UEGW 2026

AbbVie said it will present 20 new scientific abstracts from its inflammatory bowel disease (IBD) portfolio at the 2026 United European Gastroenterology (UEG) Week, held October 17 to 20 in Barcelona, Spain. The data include established therapies studied over longer periods and in real-world practice. Sofie Berg, Pharm.D., Ph.D., therapeutic area head, immunology, international medical affairs at AbbVie, said Crohn's disease and ulcerative colitis are chronic, lifelong conditions.

In ulcerative colitis, risankizumab data from the COMMAND study showed sustained clinical and endoscopic outcomes up to three years of maintenance treatment. As-observed clinical remission rates of 54.0% to 73.1% and endoscopic remission rates of 38.8% to 53.5% were achieved at week 96 with 180 mg, across advanced therapy-naive and advanced therapy-experienced patients.

For upadacitinib in Crohn's disease, as-observed analyses from the U-ENDURE study showed clinical and endoscopic outcomes were maintained through approximately four years of treatment. At week 144, clinical remission was achieved by 78.9% of patients receiving 15 mg and 86.6% receiving 30 mg, and endoscopic remission by 47.1% and 64.2% of patients, respectively.

Interim results from the real-world UPlift study showed that 70.2% of evaluable patients (N=497) with moderate to severe Crohn's disease achieved clinical response with upadacitinib within 12 weeks, with a median time to first response of 13 days.

The company said data evaluating endoscopic remission with investigational dual-targeting therapy ABBV-466 in moderate-to-severe Crohn's disease will also be presented in a late-breaking session on Monday, 19 October, from 10:00 to 11:00. ABBV-466 combines risankizumab, an IL-23 inhibitor, with trosunilimab, an α4β7 inhibitor. The company said ABBV-466 is investigational and its safety and efficacy have not been established by regulatory authorities.